<DOC>
	<DOCNO>NCT00855335</DOCNO>
	<brief_summary>The purpose study study change body pregnancy influence blood level TMC114 ( darunavir ) ritonavir take together , darunavir cobicistat take fixed-dose combination , TMC125 ( etravirine ) take alone darunavir ritonavir rilpivirine patient human immunodeficiency virus-1 ( HIV-1 ) . This study examine drug absorb body , distribute within body remove body time . Any pregnant woman currently receive darunavir ritonavir , darunavir cobicistat , etravirine rilpivirine HIV-1 , meet eligibility criterion study , allow enroll . Patients must willing remain study medication course pregnancy , 12 week postpartum . The information collect may help answer question best prescribe three drug pregnant woman .</brief_summary>
	<brief_title>A Single-arm , Open-label , Study Assess Pharmacokinetics Darunavir Ritonavir , Darunavir Cobicistat , Etravirine , Rilpivirine HIV-1 Infected Pregnant Women</brief_title>
	<detailed_description>There many biological change occur pregnancy , may affect way HIV medication absorb , distribute remove within body . Some medication use HIV treatment pregnancy , little known pregnancy affect class drug use study . To participate study , patient must receive 600mg TMC114 ( darunavir ) take 100mg ritonavir twice daily 800mg TMC114 ( darunavir ) 100mg ritonavir daily 800 mg darunavir take 150mg cobicistat take daily 200mg TMC125 ( etravirine ) ( without darunavir/ ritonavir ) take twice daily 25mg TMC278 ( rilpivirine ) take daily plus additional antiretroviral drug need construct active antiretroviral regimen . Darunavir ritonavir , darunavir cobicistat , etravirine , rilpivirine supply study participant . Darunavir ritonavir human immunodeficiency virus ( HIV ) protease inhibitor ( PIs ) ; cobicistat pharmacoenhancer boost level darunavir anti-HIV activity ; etravirine rilpivirine non-nucleoside reverse transcriptase inhibitor ( NNRTI ) HIV . Twelve-hour twenty four-hour blood sample do patient three study visit : Visit 4 ( 2nd trimester ) , Visit 5 ( 3rd trimester ) , Visit 8 ( 6-12 week postpartum ) . Eight blood draw take visit : One prior intake study medication , one seven post-dose sample time-points ( hour 1 , 2 , 3 , 4 , 6 , 9 12 ) . The study design primarily examine pharmacokinetics darunavir/ritonavir ( darunavir/r ) , darunavir/ cobicistat , etravirine rilpivirine second third trimester gestation , well postpartum . Pharmacokinetics measure body absorbs , distribute excretes medication . The study also examine change anti-viral activity pregnancy , postpartum period . It note safety tolerability medication use mother , measure level darunavir/ritonavir , darunavir/ cobicistat , etravirine rilpivirine newborn 's cord blood time delivery ; outcomes mother child assess well . During treatment period , patient see regular visit clinic , investigator assess patient 's medical condition , Adverse Events study drug compliance . Laboratory evaluation efficacy safety do regular visit well blood pressure monitoring . Up forty-eight ( 48 ) HIV positive pregnant woman participate study . Study enrollment close 12 evaluable patient take darunavir/ritonavir daily , 12 evaluable patient take darunavir/cobicistat daily , 12 evaluable patient take darunavir/ritonavir twice daily , 12 evaluable patient take etravirine take twice daily 12 evaluable patient take rilpivirine daily enrol . The study conduct approximately 14 research center United States 1 Puerto Rico . In order participate , patient must pregnant 13-24 week . The primary purpose ( outcome ) study assess influence pregnancy pharmacokinetics darunavir/ritonavir , darunavir/ cobicistat , etravirine rilpivirine second third trimester gestation , well postpartum . Darunavir : One 600 mg two 300 mg tablet take twice daily mouth ( two four tablet day total ) . Ritonavir : 100mg tablet take twice daily mouth ( two tablet day total ) , together darunavir . Darunavir : Two 400 mg tablet take daily mouth ( two tablet day total ) . Ritonavir : 100mg tablet take daily mouth ( one tablet day total ) , together darunavir . Darunavir/ cobicistat : fix dose combination contain 800mg darunavir 150mg cobicistat . Etravirine : Two 100 mg tablet take twice daily mouth ( four tablet day total ) . Rilpivirine : One 25mg tablet take daily mouth ( one tablet day total ) . Study medication give baseline visit ( second pregnancy trimester ) Visit 8 ( 12 week delivery ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Pregnant female ( 1826 week gestation ) document HIV1 infection Receiving darunavir/ritonavir , darunavir/cobicistat , etravirine , rilpivirine time study entry Willing remain darunavir/ritonavir , darunavir/cobicistat , etravirine , rilpivirine well background regimen , duration study , include 12 week postpartum Able comply protocol requirement provide write informed consent . Patients currently active acquire immune deficiency syndrome ( AIDS ) define illness AIDSrelated opportunistic infection Patients use cytokine inhibitor ( e.g. , thalidomide ) , anabolic hormone , cytokine ( e.g. , IL2 , INF ) , efavirenz , hydroxyurea , oral hypoglycemics , systemic chemotherapy know teratogenic agent Use investigational agent within 90 day Any known fetal anomaly Any current obstetric complication , include multiple gestation preterm labor Hepatitis B and/or C virus infection Grade 2 high anemia Thyroid disease Uncontrolled Diabetes Mellitus Types I II , gestational diabetes , determine investigator</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Postpartum</keyword>
	<keyword>Human immunodeficiency virus</keyword>
	<keyword>PREZISTA</keyword>
	<keyword>INTELENCE</keyword>
	<keyword>NORVIR</keyword>
	<keyword>TMC114</keyword>
	<keyword>TMC125</keyword>
	<keyword>darunavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>etravirine</keyword>
	<keyword>rilpivirine</keyword>
	<keyword>TMC278</keyword>
	<keyword>Cobicistat</keyword>
	<keyword>treatment experience</keyword>
</DOC>